Helps diagnose adult growth hormone deficiency (AGHD). Sold as Macrilen. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Macimorelin Acetate (sold as Macrilen), first approved Dec 20, 2017, with 1 new use approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 20, 2017 | MacrilenNDA 205598 · New molecular entity | Aeterna Zentaris | 2 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
